7 results
Primary Objective* To compare the objective response rate and overall survival of BMS-936558 to investigator*s choice in subjects with advanced melanoma.Secondary Objectives* To compare the progression-free survival (PFS) of BMS-936558 to…
Primary ObjectiveTo compare the objective response rate and overall surival of BMS-936558 versus docetaxel in subjects with squamous cell NSCLC after failure of prior platinum-based chemotherapySecondary ObjectivesTo compare the progression-free…
Research Hypothesis: Treatment with nivolumab (BMS-936558) will lead to clinical benefit, as demonstrated by a clinically meaningful objective response rate, including durable responses with substantial magnitude of tumor burden reduction.Primary…
The main research question is whether or not the administration of nivolumab increases "overall response rate" (ORR) in patients with classical Hodgkin Lymphoma who have progressed or relapsed following autologous stem cell transplant (…
In patients with neoadjuvant disease the purpose of the study is to define the safety and tolerability of the drug. In patients with metastatic disease the purpose is to determine if treatment with Nivolumab or Nivolumab and ipilimumab will lead to…
The primary objective of this study is to evaluate the pharmacodynamics (PD) (apolipoproteins/lipid particles and cholesterol efflux) of obicetrapib in cerebrospinal fluid (CSF) and plasma (apolipoproteins/lipid particles) in patients with early…
Primary Objectives* To assess the pharmacodynamic effects of systemic prednisolone on the LPS- or IMQ-induced inflammatory response* To assess safety & tolerability of intradermal LPS and topical IMQ in combination with prednisoloneSecondary…